Australia - English - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - acetylcholine chloride, quantity: 10 mg/ml - diluent, not applicable - excipient ingredients: sodium acetate; magnesium chloride hexahydrate; potassium chloride; calcium chloride dihydrate; water for injections - miochol-e is used to obtain complete miosis of the iris in seconds after placement of the intraocular lens (iol) in cataract surgery; and in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required.

New Zealand - English - Medsafe (Medicines Safety Authority)

bausch & lomb (nz) ltd - acetylcholine chloride 10 mg/ml - powder for injection - 20 mg/2ml - active: acetylcholine chloride 10 mg/ml excipient: mannitol calcium chloride dihydrate magnesium chloride hexahydrate potassium chloride sodium acetate trihydrate water for injection - miochol-e is used to obtain miosis of the iris in seconds after placement of the iol (intraocular lens) in cataract surgery and in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - cholestyramine (unii: 4b33bgi082) (cholestyramine - unii:4b33bgi082) - cholestyramine 4 g in 5.5 g - 1) cholestyramine for oral suspension usp light powder, is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [ldl] cholesterol) who do not respond adequately to diet. cholestyramine for oral suspension usp light powder may be useful to lower ldl cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. prior to initiating therapy with cholestyramine for oral suspension usp light powder secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess total cholesterol, hdl-c, and triglycerides (tg). for individuals with tg less than 400 mg/dl (< 4.5 mmol/l), ldl-c can be estimated using the following equation:- ldl-c = total cholesterol – [(tg/5) + hdl-c] for tg levels > 400 mg/dl, this equation is less accurate and ldl-c concentrations should be determined by ultracentrifugation. in hypertriglyceridemic patients, ldl-c may be low or normal despite elevated total-c. in such cases cholestyramine for oral suspension usp light powder may not be indicated. serum cholesterol and triglyceride levels should be determined periodically based on ncep guidelines to confirm initial and adequate long-term response. a favorable trend in cholesterol reduction should occur during the first month of cholestyramine for oral suspension usp light powder therapy. the therapy should be continued to sustain cholesterol reduction. if adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine for oral suspension usp light powder or adding other lipid-lowering agents in combination with cholestyramine for oral suspension usp light powder should be considered. since the goal of treatment is to lower ldl-c, the ncep4 recommends that ldl-c levels be used to initiate and assess treatment response. if ldl-c levels are not available then total-c alone may be used to monitor long-term therapy. a lipoprotein analysis (including ldl-c determination) should be carried out once a year. the ncep treatment guidelines are summarized below. * coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). * * other risk factors for coronary heart disease (chd) include: age (males ≥ 45 years; females ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature chd; current cigarette smoking; hypertension; confirmed hdl-c < 35 mg/dl (< 0.91 mmol/l); and diabetes mellitus. subtract one risk factor if hdl-c is ≥ 60 mg/dl (≥ 1.6 mmol/l). cholestyramine for oral suspension usp light powder monotherapy has been demonstrated to retard the rate of progression2,3 and increase the rate of regression3 of coronary atherosclerosis. 2) cholestyramine for oral suspension usp light powder is indicated for the relief of pruritus associated with partial biliary obstruction. cholestyramine for oral suspension usp light powder has been shown to have a variable effect on serum cholesterol in these patients. patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. cholestyramine for oral suspension usp light powder is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine and in those individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - cholestyramine (unii: 4b33bgi082) (cholestyramine - unii:4b33bgi082) - cholestyramine 4 g in 5.5 g - 1) cholestyramine for oral suspension usp light powder, is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [ldl] cholesterol) who do not respond adequately to diet. cholestyramine for oral suspension usp light powder may be useful to lower ldl cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. prior to initiating therapy with cholestyramine for oral suspension usp light powder secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess total cholesterol, hdl-c, and triglycerides (tg). for individuals with tg less than 400 mg/dl (< 4.5 mmol/l), ldl-c can be estimated using the following equation:- ldl-c = total cholesterol – [(tg/5) + hdl-c] for tg levels > 400 mg/dl, this equation is less accurate and ldl-c concentrations should be determined by ultracentrifugation. in hypertriglyceridemic patients, ldl-c may be low or normal despite elevated total-c. in such cases cholestyramine for oral suspension usp light powder may not be indicated. serum cholesterol and triglyceride levels should be determined periodically based on ncep guidelines to confirm initial and adequate long-term response. a favorable trend in cholesterol reduction should occur during the first month of cholestyramine for oral suspension usp light powder therapy. the therapy should be continued to sustain cholesterol reduction. if adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine for oral suspension usp light powder or adding other lipid-lowering agents in combination with cholestyramine for oral suspension usp light powder should be considered. since the goal of treatment is to lower ldl-c, the ncep4 recommends that ldl-c levels be used to initiate and assess treatment response. if ldl-c levels are not available then total-c alone may be used to monitor long-term therapy. a lipoprotein analysis (including ldl-c determination) should be carried out once a year. the ncep treatment guidelines are summarized below. * coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). * * other risk factors for coronary heart disease (chd) include: age (males ≥ 45 years; females ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature chd; current cigarette smoking; hypertension; confirmed hdl-c < 35 mg/dl (< 0.91 mmol/l); and diabetes mellitus. subtract one risk factor if hdl-c is ≥ 60 mg/dl (≥ 1.6 mmol/l). cholestyramine for oral suspension usp light powder monotherapy has been demonstrated to retard the rate of progression2,3 and increase the rate of regression3 of coronary atherosclerosis. 2) cholestyramine for oral suspension usp light powder is indicated for the relief of pruritus associated with partial biliary obstruction. cholestyramine for oral suspension usp light powder has been shown to have a variable effect on serum cholesterol in these patients. patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. cholestyramine for oral suspension usp light powder is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine and in those individuals who have shown hypersensitivity to any of its components.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bausch & lomb uk ltd - acetylcholine chloride - powder and solvent for solution for intraocular irrigation - 20mg

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - acetylcholine chloride (unii: af73293c2r) (acetylcholine - unii:n9yns0m02x) - acetylcholine chloride 20 mg in 2 ml - to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required. miochol-e is contraindicated in persons with a known hypersensitivity to any component of this product.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - cholestyramine (unii: 4b33bgi082) (cholestyramine - unii:4b33bgi082) - cholestyramine 4 g in 9 g - 1) cholestyramine for oral suspension usp is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [ldl] cholesterol) who do not respond adequately to diet. cholestyramine may be useful to lower ldl cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. prior to initiating therapy wi

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - cholestyramine (unii: 4b33bgi082) (cholestyramine - unii:4b33bgi082) - cholestyramine 4 g in 9 g - 1) cholestyramine for oral suspension usp is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [ldl] cholesterol) who do not respond adequately to diet. cholestyramine may be useful to lower ldl cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. prior to initiating therapy with cholestyram

United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - cholestyramine (unii: 4b33bgi082) (cholestyramine - unii:4b33bgi082) - cholestyramine 4 g in 9 g - 1) cholestyramine for oral suspension powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [ldl] cholesterol) who do not respond adequately to diet. cholestyramine for oral suspension powder may be useful to lower ldl cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. prior to initi

United States - English - NLM (National Library of Medicine)

eon labs, inc. - cholestyramine (unii: 4b33bgi082) (cholestyramine - unii:4b33bgi082) - cholestyramine 4 g in 9 g - 1) cholestyramine for oral suspension, usp powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [ldl] cholesterol) who do not respond adequately to diet. cholestyramine for oral suspension, usp powder may be useful to lower ldl cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. prio